

4DMEDICAL PARTNERS WITH THE RESPIRATORY COMPROMISE INSTITUTE FOR CLINICAL PILOT PROGRAM

Highlights

- Clinical pilot program with the Respiratory Compromise Institute ("RCI") to implement XV Lung Ventilation Analysis Software (XV LVAS™) at eight clinical sites across the U.S.
 - Program focused on utilising XV LVAS to evaluate endobronchial valve procedures to treat late-stage chronic obstructive pulmonary disease ("COPD")
 - XV LVAS uses 4DMedical's proprietary XV Technology™, which converts sequences of X-ray images into four-dimensional quantitative data by using mathematical models and algorithms
-

28 April 2021: 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company"), a medical technology company focused on commercialising its patented respiratory imaging platform, is pleased to announce that it has partnered with the Respiratory Compromise Institute ("RCI"), to implement 4DMedical's XV Lung Ventilation Analysis Software (XV LVAS™) at eight clinical sites located across the U.S.

The RCI is an alliance of professional medical societies and interested healthcare providers, with support from industry sources, established to better define respiratory compromise and explore the potential for improved solutions to reduce preventable harm and deaths.

The pilot program will focus on utilising XV LVAS to evaluate endobronchial valve procedures in treating late-stage chronic obstructive pulmonary disease ("COPD"). Specifically, 4DMedical's automated end-to-end workflow will be implemented to identify additional sources of respiratory insufficiency and subsequently inform the course of patient treatment.

4DMedical's clinical programs are an important part of the Company's commercialisation strategy, driving adoption by validating the use of XV LVAS for specific respiratory diseases in the clinic. The program's initial scope is to evaluate between 75 and 100 patients undergoing endobronchial valve procedures, in order to improve healthcare outcomes by optimising patient selection.

4DMedical Founder and CEO Andreas Fouras said:

"We are extremely proud of this opportunity to support the RCI and our partner institutions. The RCI is comprised of members recognised as world leaders in COPD clinical practice and research. 4DMedical is excited to demonstrate the capability of XV LVAS to provide unprecedented insight into pulmonary functioning, critical in analysing and managing respiratory diseases."

ENDS

Authorised on behalf of the 4DMedical Board of Directors by Andreas Fouras, CEO.

Contacts:

Corporate

Charlene Stahr
Company Secretary
companysecretary@4dmedical.com

Investor

Simon Hinsley
+ 61 401 809 653
shinsley@4dmedical.com

Media

Matthew Wright
+ 61 451 896 420
matt@nwrcommunications.com.au

About 4DMedical:

Based in Melbourne, Australia and Los Angeles, U.S., 4DMedical was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.

About the Respiratory Compromise Institute (RCI):

The RCI is an alliance of professional medical societies and interested healthcare providers that have mobilised to define the state of respiratory compromise and educate the medical community so that the onset of respiratory compromise can be detected to mitigate respiratory failure and arrest.

Together, we aim to elevate awareness surrounding this respiratory state and support the use of monitoring tools and treatments already available, so healthcare professionals can help reduce the incidence of respiratory compromise.